Standard BioTools (NASDAQ:LAB) Shares Gap Up – Here’s What Happened

Standard BioTools Inc. (NASDAQ:LAB) shares gapped up before the market opened on Monday . The stock had previously closed at $1.05, but opened at $1.20. Standard BioTools shares last traded at $1.42, with a volume of 8,634,191 shares traded.

Wall Street Analyst Weigh In

Separately, KeyCorp lowered shares of Standard BioTools from an “overweight” rating to a “sector weight” rating in a research report on Thursday, February 27th.

Standard BioTools Stock Up 24.3%

The firm has a market capitalization of $495.67 million, a PE ratio of -3.70 and a beta of 1.50. The business’s 50-day moving average price is $1.09 and its 200-day moving average price is $1.34.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Standard BioTools by 80.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 554,203 shares of the company’s stock worth $970,000 after purchasing an additional 247,332 shares during the last quarter. Invesco Ltd. raised its position in shares of Standard BioTools by 7.5% during the 4th quarter. Invesco Ltd. now owns 175,041 shares of the company’s stock valued at $306,000 after acquiring an additional 12,194 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of Standard BioTools by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 83,074 shares of the company’s stock valued at $145,000 after acquiring an additional 27,334 shares during the last quarter. Northern Trust Corp boosted its position in shares of Standard BioTools by 9.3% during the fourth quarter. Northern Trust Corp now owns 2,875,160 shares of the company’s stock worth $5,032,000 after purchasing an additional 243,522 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in Standard BioTools by 27.9% during the fourth quarter. MetLife Investment Management LLC now owns 183,382 shares of the company’s stock worth $321,000 after acquiring an additional 40,057 shares in the last quarter. Institutional investors and hedge funds own 53.74% of the company’s stock.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.